title: Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
abstract: Triazolam 0.5 mg was administered to 11 dialysis patients and 11 age, weight and sex matched controls. Peak plasma concentrations (Cmax) were higher in control subjects, but there were no other differences between the groups. When dialysis patients took triazolam with 3600 mg aluminum hydroxide suspension, Cmax and AUC were increased into the range observed in control subjects. It appears that triazolam can be used at normal doses in patients with renal dysfunction, without regard to interaction with aluminum hydroxide gel, or to alterations in elimination.
authors.forename: P D
authors.initials: PD
authors.lastname: Kroboth
authors.forename: R B
authors.initials: RB
authors.lastname: Smith
authors.forename: M R
authors.initials: MR
authors.lastname: Silver
authors.forename: R
authors.initials: R
authors.lastname: Rault
authors.forename: M I
authors.initials: MI
authors.lastname: Sorkin
authors.forename: J B
authors.initials: JB
authors.lastname: Puschett
authors.forename: R P
authors.initials: RP
authors.lastname: Juhl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000536:Aluminum Hydroxide / Q000494:pharmacology*; D014151:Anti-Anxiety Agents / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D007700:Kinetics; D008875:Middle Aged; D011485:Protein Binding; D014229:Triazolam / Q000378:metabolism*
chemical_list: D014151:Anti-Anxiety Agents; D014229:Triazolam; D000536:Aluminum Hydroxide